Market Exclusive

Analyst Activity – Canaccord Genuity Reiterates Buy on Aerie Pharmaceuticals (NASDAQ:AERI)

Analyst Ratings For Aerie Pharmaceuticals (NASDAQ:AERI)

Today, Canaccord Genuity reiterated its Buy rating on Aerie Pharmaceuticals (NASDAQ:AERI) with a price target of $73.00.

There are 1 hold rating, 11 buy ratings on the stock.

The current consensus rating on Aerie Pharmaceuticals (NASDAQ:AERI) is Buy (Score: 2.92) with a consensus target price of $69.17 per share, a potential 7.82% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Aerie Pharmaceuticals (NASDAQ:AERI)
Aerie Pharmaceuticals (NASDAQ:AERI) has insider ownership of 9.36% and institutional ownership of 94.64%.

Recent Trading Activity for Aerie Pharmaceuticals (NASDAQ:AERI)
Shares of Aerie Pharmaceuticals closed the previous trading session at with shares trading hands.

Exit mobile version